How Many Silence Therapeutics plc (LON:SLN)’s Analysts Are Bullish?

February 15, 2018 - By Stephen Andrade

 How Many Silence Therapeutics plc (LON:SLN)'s Analysts Are Bullish?

Silence Therapeutics plc (LON:SLN) Ratings Coverage

Among 2 analysts covering Silence Therapeutics PLC (LON:SLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Silence Therapeutics PLC had 10 analyst reports since September 29, 2015 according to SRatingsIntel. The stock of Silence Therapeutics plc (LON:SLN) earned “Buy” rating by Peel Hunt on Monday, January 8. On Monday, January 22 the stock rating was maintained by Peel Hunt with “Buy”. On Tuesday, September 27 the stock rating was maintained by Canaccord Genuity with “Buy”. The rating was maintained by Canaccord Genuity with “Buy” on Monday, January 9. The rating was maintained by Peel Hunt with “Buy” on Thursday, February 1. The firm has “Buy” rating by Peel Hunt given on Thursday, December 28. The company was maintained on Tuesday, December 20 by Canaccord Genuity. The rating was maintained by Canaccord Genuity on Thursday, August 11 with “Buy”. The stock has “Buy” rating by Canaccord Genuity on Tuesday, September 29. Below is a list of Silence Therapeutics plc (LON:SLN) latest ratings and price target changes.

01/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
22/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
08/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 276.00 New Target: GBX 276.00 Maintain
28/12/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
14/12/2017 Broker: Peel Hunt Rating: Buy New Target: GBX 276.00 Initiates Starts

The stock decreased 0.51% or GBX 1 during the last trading session, reaching GBX 195. About 51 shares traded. Silence Therapeutics plc (LON:SLN) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company has market cap of 136.48 million GBP. The firm creates short interfering RNA molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It currently has negative earnings. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

More news for Silence Therapeutics plc (LON:SLN) were recently published by: Reuters.com, which released: “BRIEF-Silence Therapeutics Says Sold Further Part Of Holding In Arrowhead …” on December 11, 2017. Reuters.com‘s article titled: “BRIEF-Silence Therapeutics buys stake in Arrowhead Pharmaceuticals” and published on January 09, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: